Protocol Ledger

NCT05554380 · Phase II · ACTIVE NOT RECRUITING

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Interventional Phase II clinical trial protocol NCT05554380 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-22 Enrollment: 33 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05554380
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05554380
Protocol FieldVerified Registry Value
NCT IdentifierNCT05554380
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment33 participants (ESTIMATED)
Registered Start Date2023-09-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05554380
Hospital Research SiteLocationSite Profile
University of Alabama at Birmingham Cancer CenterBirmingham, ALOpen Hospital Dossier ->
Alaska Women's Cancer CareAnchorage, AKOpen Hospital Dossier ->
Kingman Regional Medical CenterKingman, AZOpen Hospital Dossier ->
PCR OncologyArroyo Grande, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI